The market for probiotics and live biotherapeutic products continues to grow, as we increase our understanding of how they can improve health. Probiotic and pharmaceutical companies are looking for ways to use the naturally occurring bacteria in our bodies to amend dysbiosis of the gut, skin and more. Then they must get their products to market, quickly and cost-effectively. But there are many challenges that will define a company’s success or failure – especially when working with living organisms, that don’t always behave the way we want. In this webcast, NIZO's multidisciplinary and multi-stage approach in the probiotic journey, from discovery to health benefit substantiation, will be explained.
NIZO supports a healthy lifestyle by substantiating health benefits of food. In this video, Marjolijn Bragt of FrieslandCampina talks about her collaboration with @NIZO in an integrated approach to build a convincing case, in which the scientific and regulatory guidance, targeted preclinical studies, well-designed clinical trials, biomarker analysis and expert interpretation are combined.
Developing infant nutrition products is a costly and time-consuming business. NIZO’s MicroColon model offers companies a solution to pre-screen ingredients, early in the development process. But could it be further optimised for the needs of infant nutrition companies? Guus explains this during this short video.
NIZO has found that dairy based proteins are the best option for medical nutrition products, Specifically high protein medical Oral Nutritional Supplement – or ONS – drinks. Given the scale and long-term potential of the market, this makes ONS drinks a very interesting opportunity for dairy producers and product manufacturers. Why are dairy proteins preferable? The other main option for use in ONS is plant-based proteins. In this webcast the functionalities of dairy and plant based proteins will be compared for ONS drinks.
NIZO supports a healthy lifestyle by substantiating health benefits of food. In this video, Ruud Albers, CEO of Nutrileads talks about his collaboration with NIZO in an integrated approach to build a convincing case, in which the scientific and regulatory guidance, targeted preclinical studies, well-designed clinical trials, biomarker analysis and expert interpretation are combined.
Provide convincing evidence that your product helps intestinal comfort, in accordance with EFSA guidelines
Around 40% of the Western population experiences digestive discomfort, such as constipation, bloating or abdominal pain. That has made intestinal health a big – and growing – business. In 2018, for example, there was a 21% increase in the launch of food and beverages making a digestive or gut health claim, in the Asia-Pacific region1.
But to make those claims, you need evidence. Through a carefully designed and performed clinical study, you can demonstrate that your fibre, prebiotic or probiotic improves intestinal comfort. Or, alternatively, that your healthy fibre does not cause gut discomfort.
NIZO can design and coordinate the execution of your study on the impact your ingredient has on gut comfort and constipation, in line with European Food Safety Authority (EFSA) requirements. For example:
With our in-house capabilities and expertise, we can create a customised study that answers your specific questions about your functional ingredient. Using validated questionnaires, we evaluate the improvement in gut comfort and constipation amongst volunteers who represent a target population suffering from intestinal discomfort.
But we can go further: enriching your clinical trial with an analysis of microbiota changes, gut health or inflammatory markers, local gut damage, etc. We not only substantiate the overall effect of your ingredient on the human body, but provide you with a deeper understanding of the mechanisms of action.